* Kezar Life Sciences Inc KZR.OQ KZR.O is expected
to show a
rise in quarterly revenue when it reports results on May 9
(estimated) for the period ending March 31 2024
* The South San Francisco California-based company is
expected to
report revenue of $400 thousand, according to the mean estimate
from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Kezar Life Sciences Inc
is for
a loss of 33 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $13.00, above its last closing price of $0.81.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.43 -0.38 -0.44 Missed -15.8
Sep. 30 2023 -0.36 -0.35 -0.32 Beat 8.4
Jun. 30 2023 -0.32 -0.32 -0.34 Missed -6.2
Mar. 31 2023 -0.29 -0.29 -0.31 Missed -7.5
Dec. -0.28 -0.25 Beat 9.6
31 2022
Sep. 30 2022 -0.27 -0.27 -0.25 Beat 7.5
Jun. 30 2022 -0.27 -0.27 -0.25 Beat 9
Jan. 1 0001 -0.28 -0.28 -0.26 Beat 8
This summary was machine generated May 7 at 11:23 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)